Idiotype vaccine strategies for treatment of follicular lymphoma

Future Oncology

Volumn 7, Issue 1, 2011, Pages 111-122

  Mahaseth, Hemchandra ^a   Brody, Joshua D ^b   Sinha, Rajni ^a   Shenoy, Pareen J ^a   Flowers, Christopher R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer vaccine; follicular lymphoma; idiotype vaccine; immunoglobulin idiotypes; immunotherapy

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; BIOVAXID; CANCER VACCINE; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DOXORUBICIN; ETOPOSIDE; FAVLD; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; KEYHOLE LIMPET HEMOCYANIN; MITOXANTRONE; MYVAX; PLACEBO; PREDNISONE; RECOMBINANT VACCINE; RITUXIMAB; SPECIFID; UNCLASSIFIED DRUG; VINCRISTINE;

B CELL LYMPHOMA; B LYMPHOCYTE; CANCER REGRESSION; CANCER RELAPSE; CELLULAR IMMUNITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; INJECTION SITE REACTION; LYMPHOCYTE PROLIFERATION; MULTIPLE CYCLE TREATMENT; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; LYMPHOMA, FOLLICULAR;

EID: 78650589626     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.159     Document Type: Review

References (64)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer Statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010).
2. Jaffe ES: The 2008 WHO classifcation of lymphomas: implications for clinical practice and translational research. Hematology Am. Soc Hematol. Educ Program 1, 523-531 (2009).
3. Jaffe ES, Raffeld M, Medeiros LJ, Stetler-Stevenson M: An overview of the classifcation of non-Hodgkin's lymphomas: an integration of morphological and phenotypical concepts. Cancer Res. 52(Suppl. 19), 5447S-5452S (1992).
4. Freedman AS: Non-transplant-related treatment options in follicular lymphoma. Biol. Blood Marrow Transplant 12(1 Suppl. 1), 53-58 (2006).
5. Jaffe ES, Shevach EM, Frank MM, Berard CW, Green I: Nodular lymphoma-evidence for origin from follicular B lymphocytes. N. Engl. J. Med. 290(15), 813-819 (1974).
6. Bloomfeld CD, Arthur DC, Frizzera G, Levine EG, Peterson BA, Gajl-Peczalska KJ: Nonrandom chromosome abnormalities in lymphoma. Cancer Res. 43(6), 2975-2984 (1983).
7. Rowley JD: Chromosome studies in the non-Hodgkin's lymphomas: the role of the 14;18 translocation. J. Clin. Oncol. 6(5), 919-925 (1988).
8. Friedberg JW, Taylor MD, Cerhan JR et al.: Follicular Lymphoma in the United States: First Report of the National LymphoCare Study J. Clin. Oncol. 27(8), 1202-1208 (2009).
9. Bendandi M: Aiming at a curative strategy for follicular lymphoma. CA Cancer J. Clin. 58(5), 305-317 (2008).
10. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin. Oncol. 20(Suppl. 5), 75-88 (1993).
11. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP: New treatment options have changed the survival of patients with follicular lymphoma. J. Clin. Oncol. 23(33), 8447-8452 (2005).
12. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK: Improved survival of follicular lymphoma patients in the United States. J. Clin. Oncol. 23(22), 5019-5026 (2005).
13. Liu Q, Fayad L, Cabanillas F et al.: Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas MD Anderson Cancer Center. J. Clin. Oncol. 24(10), 1582-1589 (2006).
14. Marcus R, Imrie K, Solal-Celigny P et al.: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J. Clin. Oncol. 26(28), 4579-4586 (2008).
15. Hiddemann W, Kneba M, Dreyling M et al.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) signifcantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12), 3725-3732 (2005).
16. Schulz H, Bohlius JF, Trelle S et al.: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J. Natl Cancer Inst. 99(9), 706-714 (2007).
17. Schulz H, Bohlius J, Skoetz N et al.: Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst. Rev. (4), CD003805 (2007).
18. Czuczman MS: CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin. Oncol. 26(5 Suppl. 14), 88-96 (1999).
19. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J. Clin. Oncol. 22(23), 4711-4716 (2004).
20. Van Besien K, Loberiza FR Jr, Bajorunaite R et al.: Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102(10), 3521-3529 (2003).
21. Rummel MJ, Niederle N, Maschmeyer G et al.: Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as frst-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: fnal results of a randomized Phase III study of the StiL (Study Group Indolent Lymphomas, Germany). ASH Annual Meeting Abstracts 114(22), 405 (2009).
22. Brody J, Levy R: Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant. Immunotherapy 1(5), 809-824 (2009).
23. Huff CA, Matsui WH, Douglas Smith B, Jones RJ: Strategies to eliminate cancer stem cells: clinical implications. Eur. J. Cancer 42(9), 1293-1297 (2006).
24. Bendandi M: Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat. Rev. Cancer 9(9), 675-681 (2009).
25. Houot R, Levy R: Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev. 23(3), 137-142 (2009).
26. Miller RA, Maloney DG, Warnke R, Levy R: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody N. Engl. J. Med. 306(9), 517-522 (1982).
27. Kaminski MS, Kitamura K, Maloney DG, Levy R: Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J. Immunol. 138(4), 1289-1296 (1987).
28. Kwak LW, Young HA, Pennington RW, Weeks SD: Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl Acad. Sci. USA 93(20), 10972-10977 (1996).
29. Carroll WL, Thielemans K, Dilley J, Levy R: Mouse x human heterohybridomas as fusion partners with human B cell tumors. J. Immunol. Methods 89(1), 61-72 (1986).
30. McCormick AA, Kumagai MH, Hanley K et al.: Rapid production of specifc vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc. Natl Acad. Sci. USA 96(2), 703-708 (1999).
31. Ardeshna KM, Smith P, Norton A et al.: Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362(9383), 516-522 (2003).
32. Hurvitz SA, Timmerman JM: Current status of therapeutic vaccines for non-Hodgkin's lymphoma. Curr. Opin. Oncol. 17(5), 432-440 (2005).
33. Flowers CR: BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma. Expert Rev. Vaccines 6(3), 307-317 (2007).
34. Barrios Y, Cabrera R, Yanez R et al.: Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica 87(4), 400-407 (2002).
35. Bendandi M, Gocke CD, Kobrin CB et al.: Complete molecular remissions induced by patient-specifc vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5(10), 1171-1177 (1999).
36. Hsu FJ, Caspar CB, Czerwinski D et al.: Tumor-specifc idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 89(9), 3129-3135 (1997).
37. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327(17), 1209-1215 (1992).
38. Redfern CH, Guthrie TH, Bessudo A et al.: Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J. Clin. Oncol. 24(19), 3107-3112 (2006).
39. Inoges S, Rodriguez-Calvillo M, Zabalegui N et al.: Clinical beneft associated with idiotypic vaccination in patients with follicular lymphoma. J. Natl Cancer Inst. 98(18), 1292-1301 (2006).
40. Longo DL: Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure. J. Natl Cancer Inst. 98(18), 1263-1265 (2006).
41. Timmerman J, Levy R, Czerwinski D, Ingolia D, Denney DW, Kunkel L: A Phase II trial to evaluate the effcacy of recombinant idiotype vaccines in untreated follicular non-Hodgkin's lymphoma in the 'watch-and-wait' period. Proc. Am. Soc Clin. Oncol. 21 (2002) (Abstract 13).
42. Schuster SJ, Neelapu SS, Gause BL et al.: Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in frst complete remission: Phase III clinical trial results. J. Clin. Oncol. 27(18S), (2009).
43. Freedman A, Neelapu SS, Nichols C et al.: Placebo-controlled Phase III trial of patient-specifc immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J. Clin. Oncol. 27(18), 3036-3043 (2009).
44. Levy R, Robertson M, Ganjoo K, Leonard J, Vose J, Denney D: Results of a Phase III trial evaluating safety and effcacy of specifc immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specifc immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma (fNHL). AACR annual meeting (2008) (Abstract LB-204).
45. Timmerman JM, Vose JM, Czerwinski DK et al.: Tumor-specifc recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk. Lymphoma 50(1), 37-46 (2009).
46. Leonard JP, Mason K, Theriault T et al.: Preliminary immune response (IR) results of a Phase II study with idiotype (Id) immunotherapy after treatment with CVP and rituximab for follicular non-Hodgkin's lymphoma (FL). J. Clin. Oncol. 24(Suppl. 18), 7529 (2006).
47. Koc O, Redfern C, Wiernik P et al.: Active Immunotherapy with mitumprotimut-T (FavId®, Id-KLH) following rituximab induction in patients (pts) with follicular B-cell lymphoma (FL): progression free survival (PFS) at 4-year follow up. Blood (ASH Annual Meeting Abstracts) 110, 2567 (2007).
48. Koc ON, Redfern C, Wiernik PH et al.: Continued late conversion to complete remission (CR/CRu) and durability of remission (DUR) in pts with B-cell follicular lymphoma (FL) treated with rituximab followed by mitumprotimut-T (Id-KLH, FavId®) active immunotherapy. Blood (ASH Annual Meeting Abstracts) 110(3427), (2007).
49. Solal-Celigny P, Roy P, Colombat P et al.: Follicular lymphoma international prognostic index. Blood 104(5), 1258-1265 (2004).
50. Bendandi M: Clinical beneft of idiotype vaccines: too many trials for a clever demonstration? Rev. Recent Clin. Trials 1(1), 67-74 (2006).
51. De Cerio AL, Inoges S: Future of idiotypic vaccination for B-cell lymphoma. Expert Rev. Vaccines 8(1), 43-50 (2009).
52. Lin RY, Levin M, Nygren EN, Norman A, Lorenzana FG: Assessment of platelet antibody by fow cytometric and ELISA techniques: a comparison study. J. Lab. Clin. Med. 116(4), 479-486 (1990).
53. Smyth MJ, Thia KYT, Street SEA, MacGregor D, Godfrey DI, Trapani JA: Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192(5), 755-760 (2000).
54. Salles GA, Seymour JF, Feugier P et al.: Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. J. Clin. Oncol. 2010 ASCO Annual Meeting Proceedings 28(S15), (2010) (Abstract 8004).
55. Morschhauser F, Radford J, Van Hoof A et al.: Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after frst remission in advanced follicular lymphoma. J. Clin. Oncol. 26(32), 5156-5164 (2008).
56. Betting DJ, Kaf K, Abdollahi-Fard A, Hurvitz SA, Timmerman JM: Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas. J. Immunol. 181(6), 4131-4140 (2008).
57. Timmerman JM, Czerwinski DK, Davis TA et al.: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99(5), 1517-1526 (2002).
58. O'Mahony D, Morris JC, Quinn C et al.: A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy Clin. Cancer Res. 13(3), 958-964 (2007).
59. Neelapu SS, Gause BL, Nikcevich DA et al.: Phase III randomized trial of patient-specifc vaccination for previously untreated patients with follicular lymphoma in frst complete remission: protocol summary and interim report. Clin. Lymphoma 6(1), 61-64 (2005).
60. Davis TA, Hsu FJ, Caspar CB et al.: Idiotype vaccination following ABMT can stimulate specifc anti-idiotype immune responses in patients with B-cell lymphoma. Biol. Blood Marrow Transplant 7(9), 517-522 (2001).
61. Bendandi M, Marillonnet S, Kandzia R et al.: Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. Ann. Oncol. DOI: 10.1093/annonc/mdq256 (2010) (Epub ahead of print).
62. McCormick AA, Reddy S, Reinl SJ et al.: Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a Phase I clinical study Proc. Natl Acad. Sci. USA 105(29), 10131-10136 (2008).
63. Kanter G, Yang J, Voloshin A, Levy S, Swartz JR, Levy R: Cell-free production of scFv fusion proteins: an effcient approach for personalized lymphoma vaccines. Blood 109(8), 3393-3399 (2007).
64. Neelapu SS, Baskar S, Gause BL et al.: Human autologous tumor-specifc T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin. Cancer Res. 10(24), 8309-8317 (2004).